Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polyclonal Treg Adoptive Immunotherapy in Renal Transplant Recipients
NCT02088931Phase 1Completed
- Sponsor
- University of California, San Francisco
- Start
- Mar 2014
- Primary completion
- Dec 2016
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CLBS03 in kidney transplant rejection, sponsored by University of California, San Francisco. Primary endpoints: Number of Patients with Adverse Events at 1 year, Patient Survival at 3 years and 2 more. Started Mar 2014; status: completed.
02
Drugs
CLBS03
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT02088931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02088931.